ArticleCell research2014
Persistent hepatitis C virus infections and hepatopathological manifestations in immune-competent humanized mice.
Article in Cell research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 61 citations in OpenAlex.
- Hepatitis C virus inhibits the E2F2/PI3K/AKT signaling pathway through miR-378b and leads to glycolipid metabolism disorders in the liver.Molecular biology reports · 2026Article
- Cell surface protein-protein interaction profiling for biological network analysis and novel target discovery.Life medicine · 2024Review
- EGFR core fucosylation, induced by hepatitis C virus, promotes TRIM40-mediated-RIG-I ubiquitination and suppresses interferon-I antiviral defenses.Nature communications · 2024Article
- Enhanced host immune responses in presence of HCV facilitate HBV clearance in coinfection.Virologica Sinica · 2022Article
- In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?World journal of hepatology · 2021Review
- Advances in Transgenic Mouse Models to Study Infections by Human Pathogenic Viruses.International journal of molecular sciences · 2020Review
- Animal Models of Hepatitis C Virus Infection.Cold Spring Harbor perspectives in medicine · 2020Review
- Use of an Outbred Rat Hepacivirus Challenge Model for Design and Evaluation of Efficacy of Different Immunization Strategies for Hepatitis C Virus.Hepatology (Baltimore, Md.) · 2020Article
- Hepatitis C Virus Vaccine: Challenges and Prospects.Vaccines · 2020Review
- NKG2A is a NK cell exhaustion checkpoint for HCV persistence.Nature communications · 2019Article
- Identification of serotonin 2A receptor as a novel HCV entry factor by a chemical biology strategy.Protein & cell · 2019Article
- Mouse Models for Studying HCV Vaccines and Therapeutic Antibodies.Methods in molecular biology (Clifton, N.J.) · 2019Article
- CD2-Associated Protein Contributes to Hepatitis C, Virus Propagation and Steatosis by Disrupting Insulin Signaling.Hepatology (Baltimore, Md.) · 2018Article
- Histone Deacetylase 3 Inhibitor Suppresses Hepatitis C Virus Replication by Regulating Apo-A1 and LEAP-1 Expression.Virologica Sinica · 2018Article
- Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research.Nature reviews. Gastroenterology & hepatology · 2018Review
- Animal Models to Study Hepatitis C Virus Infection.Frontiers in immunology · 2018Review
- Quinolinate Phosphoribosyltransferase is an Antiviral Host Factor Against Hepatitis C Virus Infection.Scientific reports · 2017Article
- Enterovirus 71 infection impairs the reproductive capacity of female mice.Experimental and therapeutic medicine · 2017Article
- Epidemiology and Synergistic Hepatopathology of Malaria and Hepatitis C Virus Coinfection.Virology : research and treatment · 2017Review
- Article
Corrections and comments
- Commented on by
Authors and funding
18 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The majority of hepatitis C virus (HCV) infection develops chronic infection, which causes steatosis, cirrhosis and hepatocellular carcinoma. However, understanding HCV chronicity and pathogenesis is hampered by its narrow host range, mostly restricted to human and chimpanzee. Recent endeavour to infect a variety of humanized mice has not been able to achieve persistent HCV infection unless the essential innate immune responsive genes are knocked out. Nevertheless, such immune-compromised humanized mice still lacked HCV infection-induced hepatopathogenesis. Here we report that transgenic mice in ICR background harboring both human CD81 and occludin genes (C/O(Tg)) are permissive to HCV infection at a chronicity rate comparable to humans. In this mouse model, HCV accomplishes its replication cycle, leading to sustained viremia and infectivity for more than 12 months post infection with expected fibrotic and cirrhotic progression. Host factors favorable for HCV replication, and inadequate innate immune-response may contribute to the persistence. Lastly, NS3/4 protease inhibitor telaprevir can effectively inhibit de novo RNA synthesis and acute HCV infection of C/O(Tg) mice. Thus, chronic HCV infection with complete replication cycle and hepatopathologic manifestations is recapitulated, for the first time, in immune-competent mice. This model will open a new venue to study the mechanisms of chronic hepatitis C and develop better treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.